@article{cbf346d682c54b5d87a99b73431f8ce0,
title = "Psychopharmacologic Treatment of Schizophrenia in Adolescents and Children",
abstract = "An increasing number of antipsychotic medications have demonstrated efficacy in randomized placebo-controlled trials in the treatment of children and adolescents with schizophrenia. This review summarizes and synthesizes relevant antipsychotic medication studies, with particular emphasis on second-generation agents, and discusses other clinical considerations that may influence medication selection. With the exception of clozapine demonstrating superior efficacy in the improvement of psychotic symptoms in treatment-resistant patients, many antipsychotic agents have been shown to be similarly efficacious, including first-generation medications. Consideration of the side-effect profile, which can differ substantially from medication to medication, is essential when choosing treatment options.",
keywords = "Adolescents, Antipsychotic medication, Antipsychotic side effects, Children, Psychopharmacology, Psychosis, Schizophrenia",
author = "Lee, {Esther S.} and Hal Kronsberg and Findling, {Robert L.}",
note = "Funding Information: In the past 36 months, Dr. Findling receives or has received research support, acted as a consultant and/or has received honoraria from Acadia, Aevi, Akili, Alcobra, Allergan, Amerex, American Academy of Child & Adolescent Psychiatry, American Psychiatric Press, Arbor, Bracket, Daiichi-Sankyo, Epharma Solutions, Forest, Genentech, Ironshore, KemPharm, Luminopia, Lundbeck, Merck, NIH, Neurim, Noven, Nuvelution, Otsuka, PCORI, Pfizer, Physicians Postgraduate Press, Purinix, Receptor Life Sciences, Roche, Sage, Shire, Sunovion, Supernus Pharmaceuticals, Syneurx, Teva, TouchPoint, Tris, and Validus. Dr Findling discloses the following past or present relationships with the following commercial organizations that could be perceived as a conflict of interest in the past 36 months: Acadia, consultant fees; Aevi, grant research support and consultant fees; Akili, grant research support and consultant fees; Alcobra, grant research support and consultant fees; Allergan, grant research support and consultant fees; Amerex, consultant fees; Am Acad CAP, royalties; American Psychiatric Press, royalties; Arbor, consultant fees; Bracket, honoraria; Daiichi-Sankyo, royalties; Epharma Solutions, consultant fees; Forest, grant research support; Genentech, consultant fees; Ironshore, consultant fees; KemPharm, consultant fees; Luminopia, consultant fees; Lundbeck, grant research support and consultant fees; Merck, consultant fees; NIH, grant research support and consultant fees; Neurim, grant research support and consultant fees; Noven, consultant fees; Nuvelution, consultant fees; Otsuka, consultant fees; PCORI, grant research support; Pfizer, grant research support; Physicians Postgraduate Press, consultant fees; Purinix, consultant fees; Receptor Life Sciences, consultant fees; Roche, grant research support; Sage, royalties; Shire, grant research support and consultant fees; Sunovion, grant research support and consultant fees; Supernus Pharmaceuticals, grant research support, consultant fees; Syneurx, grant research support; Teva, consultant fees; Touchpoint, consultant; Tris, consultant; Validus, grant research support and consultant fees. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2020",
month = jan,
doi = "10.1016/j.chc.2019.08.009",
language = "English (US)",
volume = "29",
pages = "183--210",
journal = "Child and Adolescent Psychiatric Clinics of North America",
issn = "1056-4993",
publisher = "W.B. Saunders Ltd",
number = "1",
}